Clover Biopharmaceuticals Strikes Cap-Limited Settlement With Gavi to End Arbitration

Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has shared an update.

Clover Biopharmaceuticals has reached a settlement with global vaccine alliance Gavi over a dispute concerning repayment of US$224 million in advance purchase funds. Under the agreement, wholly owned subsidiary Clover HK will make a US$7 million upfront cash payment, followed by semi-annual deferred payments and success-based payments tied to future financings, business development income and product sales, all capped in the mid double-digit millions over 12 years.

The company characterizes the settlement as a commercially prudent resolution that removes litigation uncertainty and improves visibility for its strategic plans. By capping its potential outflows and avoiding further arbitration risk, Clover aims to focus resources on advancing its key respiratory combination vaccine candidates SCB-1022 and SCB-1033, a move that could strengthen its positioning in the competitive vaccine market and provide clearer prospects for shareholders and potential investors.

The most recent analyst rating on (HK:2197) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.

More about Clover Biopharmaceuticals Ltd.

Clover Biopharmaceuticals, Ltd. is a Hong Kong-listed biopharmaceutical company focused on developing proprietary respiratory vaccine candidates. Its pipeline includes combination vaccines such as SCB-1022 and SCB-1033, targeting RSV, hMPV and PIV3 to address significant unmet needs in global respiratory disease prevention.

Average Trading Volume: 3,876,561

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.75B

For detailed information about 2197 stock, go to TipRanks’ Stock Analysis page.